Berkshire Hathaway Bets Big on UnitedHealth Amid Regulatory Scrutiny

Warren Buffett’s Berkshire Hathaway has made a significant investment move, establishing a major position in UnitedHealth Group despite the healthcare giant facing substantial regulatory pressure. This unexpected vote of confidence from the legendary investor comes as the company navigates a Justice Department investigation into its Medicare billing practices.

Market sentiment toward UnitedHealth appears to be shifting positively, with two prominent investment banks recently upgrading their outlooks. Bernstein raised its price target substantially from $337 to $379 while maintaining its “Outperform” rating on the stock. Shortly afterward, Barclays followed with its own upgrade, increasing its target from $337 to $352 and keeping its “Overweight” recommendation in place.

These revised assessments from respected financial institutions signal a potential revaluation of UnitedHealth’s prospects, Read more...